Rejuva Gene Therapy Platform
Rejuva is preclinical and has yet to be assessed by regulatory agencies.
T2D PROGRESSION IS DRIVEN BY DECLINING PANCREATIC FUNCTION AND INSULIN PRODUCTION
PANCREATIC ISLETS
DISEASE PROGRESSION
Figures adapted from: 1. Chen et al. Mol Metab. 2017 6:943-957. 2. Biondi et al. Int J Mol Sci. 2022 23:5522
PANCREATIC GENE THERAPY (PGTx) TO IMPROVE ISLET FUNCTION
AAV-delivered glucagon-like peptide 1 receptor agonist (GLP1RA) gene therapy
REJUVA IS A MODULAR PHYSIOLOGIC GENE THERAPY WITH 3 KEY ELEMENTS
Leverage our proprietary system to enable local, low dose virus delivery directly to pancreas
Vectors with high transduction efficiency and limited systemic biodistribution
Durable alteration of metabolic hormone response in the islets with tissue-restricted transgenes
REJUVA DEVELOPMENT PIPELINE IN T2D AND OBESITY
** Product candidates under our Rejuva gene therapy platform will undergo Phase 1, Phase 2 and Phase 3 clinical trials. IND = Investigational New Drug Application with FDA or comparable regulatory body; ADA=antidiabetic agents, POC = Proof of Concept